Home › Funds › GSA CAPITAL PARTNERS LLP › IOVA
GSA CAPITAL PARTNERS LLP position in IOVA
IOVANCE BIOTHERAPEUTICS INC · Health Care
GSA CAPITAL PARTNERS LLP reported holding 293,959 shares of IOVA (IOVANCE BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.26% of its reported portfolio and ranking #20 among its reported holdings. GSA CAPITAL PARTNERS LLP has disclosed IOVA holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How GSA CAPITAL PARTNERS LLP's IOVA position evolved
GSA CAPITAL PARTNERS LLP first disclosed a stake in IOVA in Q1 2024 at 61,225 shares (US$907K). The position peaked in Q3 2026 at 293,959 shares, worth US$4.4M. Across 9 filings, GSA CAPITAL PARTNERS LLP increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 293,959 shares valued at US$4.4M — a reduction of -361,359 shares quarter over quarter.. Notable position changes include a 658% increase in Q2 2025 (shares rose 26% over the following quarter), a 60% trim in Q3 2025 (shares rose 26% over the following quarter), a 1002% increase in Q4 2025 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 61.23K | $907.00K | New |
| Q3 2024 | 25.82K | $242.00K | New |
| Q1 2025 | 25.93K | $86.00K | New |
| Q2 2025 | 196.61K | $338.00K | Add |
| Q3 2025 | 79.22K | $172.00K | Reduce |
| Q4 2025 | 872.99K | $2.38M | Add |
| Q1 2026 | 557.09K | $1.96M | Reduce |
| Q2 2026 | 655.32K | $2.73M | Add |
| Q3 2026 | 293.96K | $4.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IOVA and 13F data
IOVA (IOVANCE BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in IOVA — the largest reported positions include MHR FUND MANAGEMENT LLC (US$120.5M), Rhenman & Partners Asset Management AB (US$37.1M), Orion Investment Co (US$30.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IOVA
- MHR FUND MANAGEMENT LLC 28.97M sh · $120.50M · Q2 2026
- Rhenman & Partners Asset Management AB 2.50M sh · $37.09M · Q3 2026
- Orion Investment Co 2.08M sh · $30.88M · Q3 2026
- 683 Capital Management, LLC 2.04M sh · $30.24M · Q3 2026
- XCELSIOR ADVISOR PARTNERS LLC 1.84M sh · $27.29M · Q3 2026
- Palo Alto Investors LP 5.30M sh · $22.03M · Q2 2026
- C WorldWide Group Holding A/S 1.26M sh · $18.67M · Q3 2026
- Knott David M Jr 1.17M sh · $17.27M · Q3 2026
- Mirador Capital Partners LP 1.10M sh · $16.24M · Q3 2026
More on GSA CAPITAL PARTNERS LLP
FAQ
How long has GSA CAPITAL PARTNERS LLP held IOVA?
GSA CAPITAL PARTNERS LLP has disclosed IOVA holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is GSA CAPITAL PARTNERS LLP's current position in IOVA?
As of Q3 2026, GSA CAPITAL PARTNERS LLP holds 293.96K shares of IOVA (IOVANCE BIOTHERAPEUTICS INC), valued at $4.36M, representing 0.26% of its reported portfolio and ranking #20.
Has GSA CAPITAL PARTNERS LLP been buying or selling IOVA?
In the latest 13F filing (Q3 2026), GSA CAPITAL PARTNERS LLP reduced its position in IOVA. The position peaked in Q3 2026 at 293.96K shares.
Which other funds hold IOVA?
Other major institutional holders of IOVA include MHR FUND MANAGEMENT LLC, Rhenman & Partners Asset Management AB, Orion Investment Co, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.